Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Critical Outcome - Investor Presentation - January 2014


Published on

Published in: Health & Medicine, Business
  • Be the first to comment

Critical Outcome - Investor Presentation - January 2014

  1. 1. The future of drug discovery has arrived TSX-V: COT | January 2014
  2. 2. Disclaimer When used anywhere in this presentation, whether oral or written, the words expects, believes, anticipates, estimates and similar expressions are intended to identify forward-looking statements. Forward-looking statements may include statements addressing future financial and operating results of Critical Outcome Technologies Inc. (COTI). COTI bases these forward-looking statements on its current expectations about future events. Such statements are subject to risks and uncertainties including, but not limited to, the successful implementation of COTI’s strategic plans, the acceptance of new products, the obsolescence of existing products, the resolution of potential patent issues, competition, changes in economic conditions, and other risks described in COTI’s public documents such as press releases and filings with the Toronto Stock Exchange and the Ontario Securities Commission. All forward-looking statements are qualified in their entirety by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this presentation. These forward-looking statements speak only as of the date of this presentation. 2
  3. 3. Who we are • A bioinformatics and accelerated drug discovery company • Established in 2005 • Listed on the TSX-V under the symbol COT 3
  4. 4. Investment highlights 1 We reduce the time, cost & risk of bringing new drugs to market 2 Scalable platform technology enables multiple concurrent projects 3 Potential cancer breakthrough is (nearly) Phase 1 ready 4
  5. 5. What we do • Reduce drug discovery, optimization & lead selection by 1.5 to 3 yrs. • Saving significant $$$ • Increasing revenue period under patent protection 5
  6. 6. How we do it CHEMSAS® • Proprietary platform technology • Artificial intelligence + proprietary algorithms + medicinal chemistry expertise 6
  7. 7. Advantages of CHEMSAS® • Computational replication of traditional ‘wet lab’ drug discovery process • Failed attempts occur quickly & cheaply in computer simulations, not the ‘research bench’ • Higher probability of clinical & commercial success 7
  8. 8. Scalable platform technology • Enables multiple concurrent revenue opportunities • 3 existing R&D collaborations - Western University - Delmar Chemicals - Major Pharma Co. • Collaborations expected to bring in multiple milestone payments beginning late 2014 / 2015 8
  9. 9. Scalable platform technology • Robust internal pipeline of compounds – COTI-2, AML, etc. • Strategy to license our own compounds – Upfront payments, milestones, royalties 9
  10. 10. Potential cancer breakthrough Our lead compound, COTI2, is effective against cancers with mutations of the p53 gene 10
  11. 11. > 50% of all human cancers have a p53 mutation (eg. ~95% of ovarian cancers) Why COTI-2 is exciting Mechanism of action confirmed by thought leader Dr. Gordon Mills at MD Anderson Cancer Center (June 2013) Novel, first in class Strong IP protection in place 11
  12. 12. COTI-2 is (nearly) Phase 1 ready • In final 2-species toxicity studies – completion in first half of 2014 • FDA filing expected mid-to-late 2014 (leading to Phase 1 clinical trial) • Pursuing orphan drug &/or breakthrough therapy status • Seeking optimal partner for clinical development 12
  13. 13. COTI-2 = significant revenue potential • Top 5 2012 Phase 1/2 oncology licensing deals disclosed (1): • Upfront payments of approx. $25-$92 million • Milestone payments between $550-$1,100 million • Royalties on net sales • 1st half of 2013 (2) – 16 phase 1 licensing deals with 6 in cancer – avg. upfront $30m (1) (2) Medius Associates Thomson Reuters 13
  14. 14. Looking ahead: Project ROSALIND • Programmable computer simulation of human cancer cell signaling • Better personalized treatment decisions based on genetic profile of one’s cancer • Personalized cancer gene profiling projected to be * ~$35B market by 2018 * Markets and Markets (2013) 14
  15. 15. The future of drug discovery has arrived Dr. Wayne Danter President & CEO Tel: (519) 858-5157